S1PR1 and relapsing-remitting multiple sclerosis: Siponimod (BAF312), an orally administered sphingosine-1-phophate receptor (S1PR) modulator binding selectively to S1PR1 and S1PR5, reduces relapse rate and inflammatory disease activity in relapsing remitting MS (RRMS) [2].